Nuvation Bio discontinues NUV-1511 DDC program; redirects $100-150M to pipeline

Nuvation Bio Inc.

Discontinued NUV-1511 due to inconsistent efficacy across cohorts; DDC platform continues.
Projected $100-150M in R&D/CMC costs through 2029 reallocated to other pipeline molecules.
First patient enrolled in part 2 of G203 study of safusidenib for IDH1-mutant glioma.
Continued investment in IBTROZI (taletrectinib) commercial launch and TRUST-IV adjuvant study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.